Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.8 EUR | -2.90% | -0.74% | -6.94% |
May. 15 | Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' | MT |
May. 15 | Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% | MT |
Sales 2024 * | 19.8B 2.88B 2.65B | Sales 2025 * | 23.62B 3.44B 3.16B | Capitalization | 129B 18.81B 17.31B |
---|---|---|---|---|---|
Net income 2024 * | 4.67B 680M 626M | Net income 2025 * | 6.61B 962M 885M | EV / Sales 2024 * | 5.26 x |
Net cash position 2024 * | 25.1B 3.65B 3.36B | Net cash position 2025 * | 32.35B 4.71B 4.33B | EV / Sales 2025 * | 4.1 x |
P/E ratio 2024 * |
29.5
x | P/E ratio 2025 * |
21.2
x | Employees | 2,286 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.5% |
Latest transcript on Genmab A/S
1 day | -2.90% | ||
1 week | -0.74% | ||
Current month | +3.08% | ||
1 month | +1.52% | ||
3 months | +1.52% | ||
6 months | -6.29% | ||
Current year | -6.94% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
Date | Price | Change |
---|---|---|
24-05-21 | 26.8 | -2.90% |
24-05-20 | 27.6 | +1.47% |
24-05-17 | 27.2 | 0.00% |
24-05-16 | 27.2 | 0.00% |
24-05-15 | 27.2 | +0.74% |
Delayed Quote Börse Stuttgart, May 21, 2024 at 10:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |
- Stock Market
- Equities
- GMAB Stock
- GE91 Stock